In the CNS, however, it was suggested that A2aR may enhance tissue injury, regardless of the underlying damage model: genetic or pharmacological inactivation of A2aR led to favourable outcomes in models of stroke [13–15], traumatic cortical brain injury [16, 17] and spinal cord damage [18, 19]. This evidence concerns the gene ADORA2A and brain injury.